203 results about "Molecular diagnostics" patented technology

The invention relates to the technical field of crossing of biomedical engineering, molecular diagnosis and nano-optical sensing, and particularly discloses a virus nucleic acid variation amplification-free LSPR (Local Surface Plasmon Resonance) detection method and chip based on a gold nano-structure. The virus nucleic acid variation amplification-free LSPR detection chip based on the gold nanostructure comprises a sample injection port, a reaction area, a washing area, a detection area and a waste liquid area, the sample injection port is used for injecting a viral nucleic acid or protein sample, a plurality of groups of probe sequences are fixed in different reaction regions of the chip, non-amplification rapid detection of viral nucleic acid variation is realized, high sensitivity and specificity are ensured, and by utilizing the unique advantages of an MSNs template branched gold nanostructure, the detection sensitivity is improved. Refractive index change caused by single base mutation is directly amplified, the capability of completing femtomole-level detection within 30 minutes is achieved, the overall detection speed is increased, rapid typing detection of viral nucleic acid variation is achieved through LSPR spectral signals under the non-amplification condition, and a portable platform is formed by integrating the LSPR spectral signals and a micro-fluidic chip.

The invention belongs to the field of nucleic acid detection and molecular biology, and particularly relates to a method and a kit for eliminating false positive results in nucleic acid amplification reaction. According to the method, after a nucleic acid amplification reaction (taking recombinase polymerase amplification, namely RPA, for example) is completed, a target amplification product is subjected to selective enzyme digestion by utilizing restriction endonuclease, non-target products (such as primer dimers and non-specific amplification products) are not cut, and meanwhile, the non-target products which are not subjected to enzyme digestion are removed by combining solid-phase separation, so that the target amplification product is obtained. Therefore, the false positive result is eliminated. The invention also discloses a kit containing the restriction enzyme. According to the method, the specificity and the signal-to-noise ratio of a nucleic acid amplification reaction, especially RPA, are remarkably improved, the cost is low, operation is easy, the method is compatible with an existing technical platform, the method is suitable for detection scenes such as clinical molecular diagnosis, environmental monitoring and food safety, and the problem of misjudgment caused by false positive signals is effectively avoided.

The application discloses an exosome small non-coding RNA molecule marker and application thereof, and belongs to the field of tumor liquid biopsy and molecular diagnosis. The exosome small non-coding RNA molecule marker is at least one of tRNA-GlyGCC-5 and sRESE; the nucleotide sequence of the tRNA-GlyGCC-5 is shown as SEQ ID NO:1; and the nucleotide sequence of the sRESE is shown as SEQ ID NO:2. The sRESE in the application is a brand new small non-coding RNA sequence, and is first discovered by the inventor, which is important for the marker of esophageal cancer and the research on disease progression mechanism. The tumor diagnosis kit provided by the application, which comprises the exosome small non-coding RNA molecule marker, is a liquid diagnosis monitoring kit with non-invasiveness, high sensitivity, high specificity and applicability to general survey or screening.

The invention belongs to the technical field of tumor molecular diagnosis and biological information analysis, and relates to a high-throughput sequencing method and system for monitoring acute lymphocytic leukemia (MRD). Through targeted sequencing with a unique molecular identifier and / or a double-chain tag, error modeling based on a background noise spectrum and statistics / machine learning pseudo variation filtering, ultra-deep accurate detection of IG / TCR cloning and related gene low-frequency variation is realized. And an artificial intelligence recurrence risk prediction model is established by combining a time sequence MRD index, cloning diversity and clinical information, and a structured clinical report is output and docked with LIS / HIS. According to the method, the sensitivity and the specificity of ALL minimal residual disease detection can be remarkably improved, dynamic evaluation on leukemia cloning evolution and recurrence risks is realized, and a reliable basis is provided for individualized treatment decision and long-term follow-up visit.

The disclosure provides compositions, methods, and systems for implementation of high-performance molecular diagnostic assays involving color combinatorics, stimulus-responsive probes, tandem probes, conjugated polymer probes, and other mechanisms for increasing the number of targets that can be simultaneously detected in a digital assay. Multiplexed detection of targets is achieved in a rapid manner, with respect to sample partitioning and target detection using multiple color channels for detection.

The invention relates to the field of molecular diagnosis and nucleic acid amplification, in particular to a recombinase polymerization amplification method based on Twinkle helicase enhancement and application of the recombinase polymerization amplification method. According to the invention, Twinkle helicase is introduced into an RPA system for the first time, and primer combination and template unlinking are assisted by utilizing ATP-dependent unlinking activity and DNA annealing activity of the Twinkle helicase, so that the amplification efficiency and the detection sensitivity are remarkably improved. The method is suitable for plasmid DNA, a high GC template and a clinical nucleic acid sample, and can be used for constructing an RPA kit containing Twinkle, so that the application of the RPA kit in pathogen detection, molecular diagnosis and on-site rapid detection is expanded. According to the invention, the defects of the existing RPA technology in sensitivity and stability are overcome, and a new solution is provided for developing a novel nucleic acid self-detection and field detection tool.

The present invention relates to a probe set for an isothermal single reaction using a split T7 promoter and a use thereof. In the present invention, a design is made to introduce a split T7 promoter into a 3-way junction structure to produce a large quantity of fluorescent RNA aptamers at an isothermal temperature in the presence of a target molecule, and a nucleic acid biomarker can be detected rapidly and conveniently with only one enzyme in one pot. The probe set allows for various applications through high-sensitivity detection of multiple nucleic acid biomarkers and detection in which analysis is performed without an additional nucleic acid extraction process. In one pot, multiplex analysis can be conducted and molecular diagnosis can be made of various entities including viruses and pathogens.

The invention relates to a unified system for the extraction and purification of biomolecules using a novel Cloudy-Precipitated (CP) Buffer and an integrated extraction device. The CP Solution remains cloudy even when heated and enables single- or multi-step workflows for isolating nucleic acids without requiring multiple buffers or organic solvents. It contains optimized concentrations of detergents, chaotropic agents, salts, and adsorbents to efficiently lyse cells and minimize processing steps. The associated device incorporates a heating and filtration system that allows separation of target molecules from inhibitors or impurities based on molecular weight. It can operate as a single- or double-step configuration with various filter membrane options. This system reduces time, labor, and environmental impact while enhancing sample quality for molecular diagnostics, research, and therapeutic applications.

The utility model discloses a multifunctional transfer device and a workstation, and relates to the technical field of molecular diagnosis. The multifunctional transfer device comprises a mounting frame, a liquid transfer part and a clamping transfer part. Wherein the liquid transferring component comprises a liquid transferring power assembly movably arranged on the mounting frame, and the liquid transferring component can move in the first linear direction through the liquid transferring power assembly to generate a liquid suction force or a liquid repelling force; the clamping transfer part comprises a plurality of clamping hands and a clamping hand driving motor, and the clamping hands are rotatably arranged on the mounting frame and are in transmission connection with the clamping hand driving motor; the liquid transfer part and the clamping hand driving motor are arranged side by side in the second linear direction perpendicular to the first linear direction; the liquid transfer part is arranged between the at least two clamping hands in a third linear direction perpendicular to the first linear direction. Therefore, the device has the advantages that the overall structure is compact, and the application range is wide.

The utility model relates to the technical field of gene detection, and particularly discloses a molecular extraction mechanism and molecular diagnosis pretreatment equipment, in the molecular extraction mechanism, a rack is provided with an extraction station capable of containing a test tube; the flapping driving assembly is arranged on the rack; a flapping piece of the flapping assembly is provided with a containing groove which extends in the Z direction and is provided with an upward opening. The flapping piece is arranged at the output end of the flapping driving assembly and can synchronously move along with the output end of the flapping driving assembly, so that the flapping part of the flapping piece flaps a sample in the test tube; the extraction driving assembly is arranged on the rack; the extraction assembly comprises a magnetic bar, and the magnetic bar is in transmission connection with the output end of the extraction driving assembly and can move into the containing groove or move out of the containing groove along with the output end of the extraction driving assembly in the Z direction. According to the arrangement, the nucleic acid extraction efficiency is improved, the possibility of being polluted is also reduced, meanwhile, the magnetic bar is prevented from being cleaned, waste generated by cleaning is reduced, and the cost is saved.

Described herein is a singleplex RT-LAMP-based tests using modified primer sets. Contrived whole blood samples containing HIV-1 or HCV virions were diluted in equal parts water and loaded directly into optimized RT-LAMP master mixes. To mitigate cold-chain storage dependence, RT-LAMP reactions were performed using a lyophilized master mix. The reactions were heated for, for example 30 minutes using a hand-held, battery-powered heating device for simultaneous virion lysis and amplification.

This invention provides a molecular diagnostic card sample introduction system, comprising a transport vessel, a sample holder, a sample tube, a molecular diagnostic card, a vacuum chamber, and a hot gun. The sample tube and the molecular diagnostic card are placed inside the sample holder, which is placed inside the transport vessel. The transport vessel transports the sample holder to the vacuum chamber. The molecular diagnostic card includes a first aspiration port, a second aspiration port, a third aspiration port, and a molecular diagnostic card cavity. The first, second, and third aspiration ports are respectively connected to the molecular diagnostic card cavity. The molecular diagnostic card also includes a non-deformable card body, and the molecular diagnostic card cavity is placed inside the non-deformable card body. The hot gun is movable to the first, second, and third aspiration ports. This system solves the technical problem of contamination during sample introduction and achieves full automation.

The invention relates to the technical field of molecular diagnosis and graphic processing, in particular to an electronic microarray chip dot matrix negative and positive judgment method based on an ISFET sensor. A chip hole site corresponds to an ISFET sensor, and after a hole bottom specific nucleic acid probe and a target sequence are hybridized and extended, the voltage of the sensor is changed. The method specifically comprises the following steps: data preprocessing: filtering median values of multi-frame electric signals of a hole site and taking a mean value; the dot matrix identification comprises the steps of threshold demarcation, Canny edge detection, circular Hough transform, optimal circle screening by Kdtree, array numbering and abnormal deletion processing to position a dot matrix; and calculating a result, extracting a signal difference value of the D1 stage and the D4 stage, evaluating numerical values of the positive quality control array and the to-be-detected sample array through a numerical value of the negative quality control array, and judging a final calculation result. According to the method, response changes are rapidly analyzed through image recognition, false detection and missing detection caused by numerical value differences in different arrays are reduced through multiple times of detection, and the detection accuracy is improved by selecting the most possible area through tickets.

The invention belongs to the technical field of biology, and relates to a bronchoalveolar lavage fluid (BALF) preserving fluid, a kit and a cytological test method. The preservation solution is composed of TCEP, N-acetylcysteine, EDTA.2Na, trehalose, Proclin300, methanol, sodium chloride and HEPES, and all the components have a synergistic effect to achieve sample viscosity removal, oxidation resistance, corrosion prevention, cell protection and pH stabilization. The preserving fluid is suitable for morphological observation and nucleic acid detection of BALF cells, and can stably preserve samples at room temperature and maintain completeness of cell membranes and clear morphological structure. The kit comprises two preparations which are mixed to form a working solution, and the working solution can be directly used for sample preservation on a sampling site. The cytological test method comprises the steps of sample collection, preservation, centrifugal slide preparation, Wright-Giemsa staining and microscopic observation. Experimental results show that preservation solutions of different formulas are compatible with a chromosome system, the cell morphology is kept stable within 3 days, the dyeing effect is good, and it is proved that the preservation system can remarkably improve the preservation stability and detection reliability of BALF samples and is suitable for cytology and molecular diagnosis application of lower respiratory diseases.

The invention relates to the field of in-vitro diagnostic reagents, in particular to application of a reagent for detecting TREM2 in preparation of a diagnostic kit for chronic kidney disease osteoporosis. The invention finds that the TREM2 signal channel is closely related to the common pathological background of chronic kidney disease and osteoporosis. Therefore, the TREM2 can be used as an expression characteristic and a molecular diagnosis marker in the chronic kidney disease-related osteoporosis, so that the chronic kidney disease-related osteoporosis can be subjected to early diagnosis. On the basis, the invention provides application of the TREM2 detection reagent in preparation of the chronic kidney disease osteoporosis diagnosis kit, and the application prospect is good.

The invention discloses a chirality-like crRNA mediated CRISPR (clustered regularly interspaced short palindromic repeats) / Cas12a one-pot detection method, and belongs to the technical field of molecular detection. The chirality-like crRNA can be used as a'delay switch 'of Cas12a activity activation, and a guided Cas12a system shows a unique delayed cutting characteristic. By means of the unique characteristics, the one-pot sensing strategy solves the problem that a Cas12a cutting system and a nucleic acid amplification system in a single reaction container are not compatible, and compared with a traditional crRNA mediated one-pot method reaction, the sensitivity is improved by 1000 times. In addition, a portable diagnostic (DFTFD) platform is constructed for on-site detection. The CRISPR / Cas12a molecular marker has great potential in promotion of application of CRISPR / Cas12a in basic research and promotion of development of a next-generation field detection molecular diagnosis platform.

The invention belongs to the field of medical diagnosis, and particularly relates to adolescent idiopathic scoliosis disease-causing gene mutation and a diagnostic reagent based on the adolescent idiopathic scoliosis disease-causing gene mutation, and it is found for the first time that the adolescent idiopathic scoliosis disease can be caused by GPER1 gene mutation (chr7: 1, 091, 747Ggt, C, hg38) through an exon sequencing technology. Research results of the invention can be used for early screening of adolescent idiopathic scoliosis virulence gene mutation carriers to provide prenatal and postnatal rearing guidance on one hand, and can provide molecular diagnosis basis for adolescent idiopathic scoliosis patients on the other hand to provide a new direction for research and development of related scientific research and medical diagnosis products on the other hand, so that the research and development of the adolescent idiopathic scoliosis virulence gene mutation carriers can be promoted. Wide application prospects and market values are realized.

Novel nanoconjugate compositions, such as nanoparticle-oligomer arrays (NOAs), and related methods for precision therapeutics and molecular diagnostics. These compositions comprise a core, optionally a nanoparticle core, and a plurality of oligomeric strands forming a dense, highly oriented three-dimensional scaffold. This scaffold architecture is engineered to position functional molecules precisely at desired distances from the core and / or the external surface, thereby controlling their physical and chemical interactions with the core and / or microenvironment, enabling distinct functionalities not observed with the functional molecules in an unstructured formulation.

Shapley values (SVs) have become an important tool to further the goal of explainability of machine learning (ML) models. However, the computational load of exact SV calculations increases exponentially with the number of attributes. Hence, the calculation of SVs for models incorporating large numbers of interpretable attributes is problematic. Molecular diagnostic tests typically seek to leverage information from hundreds or thousands of attributes, often using training sets with fewer instances. Methods are described for evaluate SVs using Monte Carlo sampling or exact calculation in polynomial time (i.e., reasonably quickly and efficiently) using the architecture of a ML model designed for robust molecular test generation, and without requiring classifier retraining.

The present invention pertains to the field of protein engineering, molecular imaging, molecular diagnostics, and biopharmaceutics. Provided herein are six unique Proteimer protein scaffolds (TEX-S2 / S3, TEX-S4, YTHDF3, PUM, DARPin, and Aca2) that demonstrate specificity and affinity comparable to antibodies across a broad range of therapeutic targets. Methods and protocols are provided for generating non-native protein aptamers, Proteimers, which are capable of binding to a diverse set of targets, including RNA, DNA, proteins, post-translational modifications, peptides, small molecules, and prosthetic groups. This platform supports the creation of biotherapeutic aptamers from Proteimer scaffolds for the treatment of various diseases.

The application discloses a modified crRNA, a light-controlled nucleic acid detection system, a kit and application, and belongs to the cross field of biotechnology, intelligent sensing and molecular diagnosis. In view of the technical defects of strong target sequence dependence and high ultraviolet irradiation requirement of the existing light-controlled CRISPR technology, the application innovatively introduces a photosensitive protection group 6-nitropiperidin oxymethyl (NPOM) at a specific key node of a stem loop skeleton of crRNA maintaining conformation. In the constant temperature amplification stage, preferred double-site cooperative modification can transiently inhibit RNP complex assembly to realize target non-interference enrichment; subsequently, only 10 mW / cm 2 of extremely low intensity ultraviolet light irradiation for 30 seconds can restore the crRNA conformation and activate the trans cleavage. The preferred technical scheme of the application can eliminate the target sequence limitation, realizes a detection limit of as low as 2 copies in a single reaction tube, and the result can be obtained within 15 minutes. The system is widely applicable to rapid diagnosis of infectious agents, high-specificity typing of single nucleotide polymorphism and portable intelligent molecular diagnosis terminal.

The invention belongs to the technical field of biomedicine and molecular diagnosis, and particularly relates to a combined marker and a risk scoring model for prognosis prediction of lung adenocarcinoma based on lactylation related genes as well as a construction method and application of the combined marker and the risk scoring model, and the combined marker comprises the following 12 genes: ANGPTL4, ITGA6, SOD1, CCL20, FKBP3, DECR1, SEMA3C, TRIM28, VEGFC, TNNC2, CRTAC1 and HGF. On the basis of sequencing data of large-scale lung adenocarcinoma samples, a group of lactylation related genes closely related to the total lifetime are systematically screened out, and a risk scoring model is constructed. According to the model, survival risk layering can be accurately carried out on the lung adenocarcinoma patient, and reliable reference is provided for clinical treatment strategy formulation and individualized management. In addition, the lactylation related genes are newly found, and the lactylation process in the lung adenocarcinoma can be understood.

The application provides a composition, a kit and a method for human cytomegalovirus detection, and relates to the technical field of molecular diagnosis.The composition comprises at least one set of human cytomegalovirus detection primer probe groups and multiplex DNA polymerase, wherein the primer probe groups comprise oligonucleotide upstream external primers, downstream external primers, upstream internal primers, downstream internal primers, upstream loop primers and downstream loop primers; the probe is a neck ring structure probe, and the multiplex DNA polymerase comprises strand displacement DNA polymerase and DNA polymerase with 5' end to 3' end exonuclease activity.The composition for human cytomegalovirus detection alleviates the technical problems that the LAMP amplification scheme in the prior art is poor in specificity and cannot realize single-tube multiplex detection.

The invention discloses an i-motif DNA (deoxyribonucleic acid) modified gold nano flare, a preparation method of the i-motif DNA modified gold nano flare and application of the i-motif DNA modified gold nano flare to detection of miRNA, and belongs to the technical field of nano biological materials and molecular diagnosis. The fluorescence probe is formed by assembling gold nanoparticles and an i-motif molecular fluorescence probe, the i-motif molecular fluorescent probe contains four sections of sequences rich in C basic groups and a target miRNA recognition chain, sulfydryl is marked at the 5'end, and fluorescent molecules are marked at the 3 'end. The probe is prepared by adopting a freeze thawing method, the labeling density of the probe is high, in a constructed detection system, the miR-21 detection limit is as low as 1.01 fM, and single-base mutants can be accurately distinguished; the technology does not need complex sample pretreatment and can be directly used for detecting cell total RNA or miRNA in a plasma sample, and the detection result is highly consistent with RT-qPCR; the problems of low marking efficiency and insufficient sensitivity in the prior art are effectively solved, and an innovative tool with high sensitivity, high specificity and clinical suitability is provided for tumor-associated miRNA molecular diagnosis.

The application discloses a kind of full-automatic nucleic acid detection analysis system and method, it belongs to medical examination testing instrument, molecular diagnostic detection instrument field, its technical key points are in at, including: consumable operation executor, it is connected with the rotating liquid transfer device of consumable and can drive rotating liquid transfer device rotation and lift and provide the power of liquid suction and liquid discharge for rotating liquid transfer device;Carriage assembly, for carrying and positioning consumable;Function warehouse processing component, for heating, magnetic separation, mixing operation of the magnetic bead lysis liquid warehouse of consumable;Reaction tube temperature control component, for the temperature adjustment of amplification reaction for consumable reaction tube;Optical assembly, for the fluorescence optical detection of solution in the reaction tube of consumable.The application aims to provide a kind of full-automatic nucleic acid detection analysis system and method, can realize sample processing, amplification, detection integrated operation.

This provides a molecular diagnostic tool useful for the efficient and accurate characterization of the discriminative and functional properties of iPSC-derived dopaminergic neurons. [Solution] A computer-based method for identifying determined dopaminergic progenitor cells within an in vitro population of neural progenitor cells is provided, comprising: receiving a test dataset containing data such as gene expression profile information relating to an in vitro population of neural progenitor cells; querying a gene expression reference database and comparing the test dataset with the gene expression reference database, wherein the gene expression reference database contains gene expression profile information of the desired determined dopaminergic progenitor cells; and outputting a computer-calculated label classification that includes an indication of whether or not the in vitro population of neural progenitor cells contains the determined dopaminergic progenitor cells.

This invention belongs to the field of molecular diagnostics, specifically relating to biomarkers for the diagnosis of herpes simplex keratitis (HSK) and their applications. This invention is the first to demonstrate that C1QA and FCERT1G are specific and reliable inflammation-related biomarkers for HSK. Diagnostic and assessment methods based on these biomarkers can provide crucial molecular evidence for the early detection, accurate diagnosis, objective severity grading, and personalized treatment of HSK. Simultaneously, this invention reveals the potential roles of FCERT1G and C1QA in HSK and provides new ideas for targeted therapy of this disease, particularly the application of goserelin as an inflammation modulator, offering a new direction for HSK treatment.

The application belongs to the technical field of food detection and molecular diagnosis, and particularly relates to a molecular diagnosis system for food source component identification. The system comprises a handheld shell, and an automatic sample processing unit, a molecular detection unit, a central control unit and a data transmission unit are integrated in the shell. The automatic sample processing unit comprises at least two processing modules and an automatic transfer mechanism, which are used for crushing, lysing and automatic transfer of a solid sample, and an in-situ cleaning and disinfecting assembly is integrated. The application realizes full-process automation, handholding and intelligence from a solid sample to a detection result, and provides an innovative solution for food safety on-site rapid detection and intelligent supervision.

This invention discloses molecular markers for lung cancer diagnosis, chemotherapy, or prognosis detection, and their applications, relating to the field of molecular diagnostics. The molecular markers include trypsin 3 splice variant 3 and the transcription factor bone marrow zinc finger gene 1 splice variant 2. By detecting the expression levels of the MZF1-V2 and PRSS3-V3 genes, lung cancer diagnosis, chemotherapy, or prognosis can be achieved. The introduction of these molecular markers has significant scientific and clinical value in personalized precision treatment applications that improve chemotherapy sensitivity. It not only provides effective molecular targets for personalized precision treatment of lung cancer patients but also provides new evidence for novel intervention strategies. Furthermore, the introduction of these molecular markers provides a more reliable means of lung cancer diagnosis and prognosis prediction.

The invention relates to a double DNA nanosphere probe (DDNS) as well as a preparation method and biosensing application thereof. The DDNS comprises a DNA (deoxyribonucleic acid) nanosphere 1 (DNS-1) and a DNA nanosphere 2 (DNS-2). The DNS-1 and the DNS-2 are respectively formed by self-assembling two cholesterol modified DNA single-stranded probes with hairpin structures, and are respectively used for identifying target miRNA and triggering a non-enzymatic circulating strand displacement amplification (T-SDA) reaction. The DDNS can realize high-sensitivity fluorescence detection on target miRNA and can effectively inhibit non-target miRNA interference, and the interference inhibition rate is close to 100%. Besides, DDNS has excellent nuclease stability, the system can automatically enter living cells without a transfection reagent, high signal-to-noise ratio fluorescence differentiation of cancer cells and healthy cells is realized on the premise of maintaining cell activity, the performance is equivalent to that of a transfection agent dependent system, and the biological safety is remarkably improved. The invention provides a new material and a new method for application of the DNA nanostructure in the fields of molecular diagnosis and precision medical treatment.